Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - amlodipine besilate,atorvastatin calcium -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - amlodipine besilate,atorvastatin calcium -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - mitozantrone hydrochloride -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - misoprostol, quantity: 200 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; hydrogenated castor oil; microcrystalline cellulose; hypromellose - cytotec is indicated in the treatment of acute duodenal and gastric ulcers. cytotec is indicated for the prevention of stress-induced upper gastrointestinal mucosal bleeding and lesions in post-surgical patients in intensive care units. cytotec is indicated for the prevention of gastric ulceration in patients in whom nsaid therapy is essential and who have been assessed at high risk of gastric ulceration, or the complications of gastric ulceration.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: maize starch; purified talc; lactose monohydrate; gelatin; quinoline yellow; titanium dioxide; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: gelatin; maize starch; quinoline yellow; titanium dioxide; lactose monohydrate; purified talc; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tinidazole -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tinidazole -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxepin hydrochloride -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isoprenaline hydrochloride -